Burkholderia pseudomallei: Difference between revisions

From IDWiki
Burkholderia pseudomallei
()
()
Line 31: Line 31:
 
**[[Pneumonia]] (50%)
 
**[[Pneumonia]] (50%)
 
**Genitourinary infection (15%)
 
**Genitourinary infection (15%)
**Skin infection (15%)
+
**Skin infection (15%), with ulcers, nodules, or abscesses
 
**Primary bacteremia (10%)
 
**Primary bacteremia (10%)
 
**Septic arthritis/OM (3-5%)
 
**Septic arthritis/OM (3-5%)
 
**Neuro (3-5%)
 
**Neuro (3-5%)
  +
**Disseminated infections can involve liver, spleen, lung, and prostate
 
*About 50% of clinical cases have bacteremia, and 20% of cases will develop septic shock
 
*About 50% of clinical cases have bacteremia, and 20% of cases will develop septic shock
 
*Can occasionally lay latent and reactivate decades after exposure
 
*Can occasionally lay latent and reactivate decades after exposure
Line 67: Line 68:
 
**Needs to be sent to CDC via NML
 
**Needs to be sent to CDC via NML
   
== Prognosis ==
+
==Prognosis==
   
* 50% mortality even with high-quality care
+
*50% mortality even with high-quality care
 
{{DISPLAYTITLE:''Burkholderia pseudomallei''}}
 
{{DISPLAYTITLE:''Burkholderia pseudomallei''}}
 
[[Category:Gram-negative bacilli]]
 
[[Category:Gram-negative bacilli]]

Revision as of 22:19, 21 July 2020

Background

Microbiology

Epidemiology

  • Humans and animals
  • Important cause of death in south-east Asia and northern Australia
    • Up to 80% seroprevalence in Thailand, mostly asymptomatic
    • More cases during the rainy season
    • Sporadic cases elsewhere, including the Middle East, Africa, and the Americas
  • May have latent disease with reactivation much later
  • Acquired by percutaneous inoculation, inhalation (esp. lab workers), and ingestion
  • Risk factors for clinical disease
    • Diabetes
    • Heavy alcohol use
    • Chronic lung disease
    • Chronic kidney disease
    • Treatment with glucocorticoids
    • Cancer
    • Thalassemia

Clinical Manifestations

  • Incubation period 9 days (range 1 to 21 days)
  • Presentations can vary from asymptomatic, skin ulcers, abscesses, latent infection, chronic pneumonia (similar to TB), or fulminant shock1
    • Pneumonia (50%)
    • Genitourinary infection (15%)
    • Skin infection (15%), with ulcers, nodules, or abscesses
    • Primary bacteremia (10%)
    • Septic arthritis/OM (3-5%)
    • Neuro (3-5%)
    • Disseminated infections can involve liver, spleen, lung, and prostate
  • About 50% of clinical cases have bacteremia, and 20% of cases will develop septic shock
  • Can occasionally lay latent and reactivate decades after exposure

Diagnosis

  • Culture
    • Blood, throat, and urine cultures should be taken from all patients with suspected melioidosis
    • Grows on blood agar, MacConkey, etc. (i.e. not a fastidious organism)
    • Can use selective colistin or polymyxin B
    • On sheep blood agar, grows as small, smooth, cream-coloured colony with metallic sheen
    • May develop a dry and wrinkled appearance after 1 to 2 days of incubation
  • MALDI-ToF is not reliable for identifying it
  • Other methods
    • PCR
    • Immunofluorescence and latex agglutination
    • Serology (acute/convalescent)

Management

Biosafety

  • Lab workers can have aerosol exposure
  • May need prophylaxis in high-risk patients
  • Monitor with serology at baseline, weeks 1 2 4 and 6 post-exposure
    • Needs to be sent to CDC via NML

Prognosis

  • 50% mortality even with high-quality care

References

  1. ^  Bart J. Currie, Linda Ward, Allen C. Cheng. David Joseph Diemert. The Epidemiology and Clinical Spectrum of Melioidosis: 540 Cases from the 20 Year Darwin Prospective Study. PLoS Neglected Tropical Diseases. 2010;4(11):e900. doi:10.1371/journal.pntd.0000900.